Persistent Inflammation as a Catalyst for Other Risk Factors in Chronic Kidney Disease
Open Access
- 1 December 2009
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Journal of the American Society of Nephrology
- Vol. 4 (Supplement), S49-S55
- https://doi.org/10.2215/cjn.02720409
Abstract
Because inflammation by now is a “traditional” finding that predicts poor outcome and cardiovascular events in the vast majority of patients with ESRD, it could be argued that inflammatory biomarkers should not longer be considered “novel” risk factors. In this review, we forward the hypothesis that, in addition to putative direct proatherogenic effects, persistent inflammation may serve as a catalyst and, in the toxic uremic milieu, modulate the effects of other concurrent vascular and nutritional risk factors. We discuss some recent observational studies, suggesting that the presence of persistent inflammation magnifies the risk for poor outcome via mechanisms related to self-enhancement of the inflammatory cascade and exacerbation of both the wasting and the vascular calcification processes. Because persistent inflammation may be the silent culprit of other commonly observed pathophysiologic alterations in chronic kidney disease, it is imperative that inflammatory markers be regularly monitored and therapeutic attempts be made to target persistent low-grade inflammation in this patient group.Keywords
This publication has 49 references indexed in Scilit:
- Soluble CD14 Levels, Interleukin 6, and Mortality Among Prevalent Hemodialysis PatientsAmerican Journal of Kidney Diseases, 2009
- CCR5 Deletion Protects Against Inflammation-Associated Mortality in Dialysis PatientsJournal of the American Society of Nephrology, 2009
- Comorbidity and Acute Clinical Events as Determinants of C-Reactive Protein Variation in Hemodialysis Patients: Implications for Patient SurvivalAmerican Journal of Kidney Diseases, 2009
- Rosuvastatin and Cardiovascular Events in Patients Undergoing HemodialysisThe New England Journal of Medicine, 2009
- Low Serum Testosterone Increases Mortality Risk among Male Dialysis PatientsJournal of the American Society of Nephrology, 2009
- IL-6 and Serum Amyloid A Synergy Mediates Angiotensin II–Induced Muscle WastingJournal of the American Society of Nephrology, 2009
- Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive ProteinThe New England Journal of Medicine, 2008
- The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targetingNature Reviews Drug Discovery, 2008
- Osteoprotegerin upregulates endothelial cell adhesion molecule response to tumor necrosis factor-α associated with induction of angiopoietin-2☆Cardiovascular Research, 2007
- Monocyte subsets differentially employ CCR2, CCR5, and CX3CR1 to accumulate within atherosclerotic plaquesJCI Insight, 2007